Back grey_arrow_rt.gif
 
 
New Intelence (etravirine) dosage approved
 
 
  On December 22, 2010, the Food and Drug Administration approved a new 200 mg Intelence (etravirine) tablet. Intelence was originally approved in 2008, in only a 100 mg tablet formulation. The new 200 mg dosage form can help reduce pill burden for patients taking Intelence.
 
The dosage Dosage and Administration section was changed to state: 200 mg (one 200 mg or two 100 mg tablets) taken twice daily following a meal.
 
Intelence is a Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI), made by Tibotec Therapeutics.
 
The revised product label, reflecting the 200 mg tablet approval can be found at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s007lbl.pdf
 
Richard Klein
 
Office of Special Health Issues Food and Drug Administration
 
Kimberly Struble
Division of Antiviral Drug Products Food and Drug Administration
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org